Briumvi 25 mg/ml, Konzentrat zur Herstellung einer Infusionslösung

7680695990010 CH-69599 Konzentrat
Briumvi 25 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
Fiches Amavita / Sun Store / Coop Vitality

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
03/12/2025
Summary of Product Characteristics
Français
03/12/2025
Summary of Product Characteristics
Italien
03/12/2025

Detailed composition

Substance Quantity Type Category
ublituximabum
150.0 MG Substance Wirkstoff (Principe actif)
natrii chloridum
- Substance HNIDK
natrii citras dihydricus
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
acidum hydrochloridum concentratum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
31.57 MG Substance HBESI

Reimbursement information

Public price
CHF 2307.55
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/07/2025

Authorization holder

Neuraxpharm Switzerland AG

6330 Cham

Authorization information

Swissmedic authorization number
69599
Drug name
Briumvi, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L04AG14
Authorization status
Z
Dispensing category
A
First authorization
06/02/2025
Authorization expiration date
05/02/2030
IT Number
07.15.0.
Domain
Human medicine
Field of application
Briumvi wird angewendet für die Behandlung von erwachsenen Patienten mit schubförmiger Multipler Sklerose (RMS) mit aktiver Erkrankung, definiert durch klinischen Befund oder Bildgebung.

Package details

Description (FR)
BRIUMVI 25 mg/ml / 150 mg / 1 flacon(s)
Description (DE)
BRIUMVI 25 mg/ml / 150 mg / 1 Durchstechflasche(n)
Market launch
01/07/2025
Narcotic (BTM)
No

Other package sizes (1)

BRIUMVI 25 mg/ml / 150 mg / 3 flacon(s)
3 DUR
GTIN: 7680695990027
View
Buy us a coffee Explore the data